Obtained GMP Certification for CDMO(Contract Development and Manufacturing Organization) in Chungju plant
11
Received approval of Fast-track for clinical trials from US FDA
01
Received approval of NS101 for phase 1b/2a clinical trials in Korea
2023
08
Obtained KGMP certification in Chungju plant
05
Received approval of NG101(RY104) for phase 1/2a clinical trials in Canada under co-development with Neuracle Genetics
04
Signed a joint development agreement with Therabest for NK cell therapy
01
Completed phase 1 clinical trial in Canada for RY103(NS101) under co-development with Neuracle Science, an ivestigational monoclonal antibody for the treatment of Alzheimer’s disease
2022
12
Signed an MOU with Protium Science for comprehensive business cooperation for CDMO business
12
Signed an MOU with Connext for comprehensive business cooperation for CDMO business
11
Signed an MOU with Therabest for business cooperation to supply pDNA samples
10
Signed an MOU with T&R Biofab for the joint development and commercializationn of next-generation hemostatic agents
08
Participated in Bioplus-Interpex Korea 2022 for partnership expansion
06
Signed an MOU with Aston Science for joint R&D and commercializing a plasmid-DNA cancer treatment vaccine
05
Signed MOU on Joint R&D for Mass Production of Cellular and Gene Therapy Agents with Samsung Medical Center
04
Signed First Agreement for Contract Manufacturing of pDNA
04
Held Completion Ceremony for Chungju Bio and Chemical Plants
2021
11
Completed Construction of Chungju Chemical Plant and Paves Foundation for Global Pharmaceutical Production Platform
10
Received Go-Ahead for Phase 1 Clinical Trial on Neuracle Science’s New Antibody Drug for Dementia
09
Signed MOU with Cellumed for Mass Production of mRNA-producing Enzymes and Development of mRNA Vaccines
05
Signed Licensing Agreement with iNtRON Biotechnology on Antifungal Drug Candidate
05
Conducted Joint R&D on Antiviral Vaccine and Rare Genetic Disease Treatment with MDimune
04
Signed Agreement to Produce and Supply Samples for Efficacy Evaluation of Anti-Fibrotic Gene Therapy
01
Unveiled New Corporate CI and Opens Upgraded Website
2020
12
Made a term (MOU) for joint development and commercialization of & PHAGERUS® vaccine and treatment with iNtRON Biotechnology
09
Entered into an agreement regarding AAV gene therapy with Neuracle Genetics
08
Entered into an agreement(MOU) on joint development and commercialization for liver fibrosis gene therapy with Neo Gene Pharm
05
Signed a technology transfer contract for commercialization of PDRN with BNF Solution Co., Ltd.
04
Secured new candidates for COVID-19 treatment
03
Signed a business agreement with Interbiome in the United States to establish and operate cGMP manufacturing facilities for virus-based gene therapy products
2019
10
Acquired ISO 37001 (corruption prevention management system) certification
07
Selected as the best job provider in Korea (Ministry of Employment and Labor)
03
Signed a memorandum of understanding for the establishment of a joint venture for commercial production of next-generation CAR-T treatments with CUROCELL.
03
Awarded an exemplary taxpayer citation (Director of National Tax Service)
02
Decision made to build chemical pharmaceuticals cGMP plant in Chungju
01
Declared vision 'BEST till 2023'
2018
10
Signed investment contract with Neuracle Genetics Co., Ltd.
09
Signed business agreement with GNP Bioscience for the development of natural medicines and health functional foods
08
Signed antibody treatment joint development contract with Neuracle Science Co., Ltd.
05
Signed joint development contract for gene therapy products with GNP Bioscience Co., Ltd.
2017
10
Signed business agreement for natural drug development with FINZELBERG, Germany
08
Commenced construction of cGMP plant for gene therapy products in Chungju
07
Vascular and neurological disease gene therapy drug approved in US for phase 3 (2nd) clinical trial for treatment of diabetic neuropathy
2016
12
Head office relocated (Yongsan-gu, Seoul → Gangnam-gu, Seoul)
09
Vascular and neurological disease gene therapy drug approved in Korea for phase 2 clinical trial for treatment of amyotrophic lateral sclerosis (ALS)
07
Vascular and neurological disease gene therapy drug approved for phase 2 clinical trial for treatment of coronary artery disease (CAD) in Korea
05
Vascular and neurological disease gene therapy designated for fast track development for treatment of amyotrophic lateral sclerosis (ALS) by the US Food and Drug Administration
2015
09
Vascular and neurological disease gene therapy drug approved for phase 3 clinical trial for treatment of chronic non-healing diabetic/ischemic ulcers (NHU)
04
Vascular and neurological disease gene therapy drug approved for phase 3 (1st) of clinical trial for treatment of diabetic neuropathy in US
2014
11
Vascular and neurological disease gene therapy drug phase 2 clinical trial for treatment of diabetic neuropathy in completed US/Korea
05
Acquired site for Chungju Bio/Chemical cGMP plant
04
Vascular and neurological disease gene therapy drug phase 2 clinical trial for treatment of critical limb ischemia (CLI) approved in US/Korea
02
Vascular and neurological disease gene therapy approved as orphan drug for treatment of amyotrophic lateral sclerosis (ALS) the US Food and Drug Administration
2013
12
Completed phase 1 clinical trial (breast cancer) in Korea for anticancer gene therapy
12
Signed global commercialization joint development contract with ViroMed Co., Ltd. for vascular and neurological disease gene therapy drug for treating amyotrophic lateral sclerosis (ALS)
2012
07
Concluded contract for exporting antibiotic arbekacin sulfate to Russia
07
Concluded technology and worldwide sales rights transfer contract with ViroMed for chronic hepatitis B DNA vaccine
2011
10
Concluded contract to export antibiotic arbekacin sulfate product/raw materials to China
07
Presented KRW 100 Billion Venture Business Award (Small and Medium Business Administration, Korea Venture Business Association)
01
Concluded contract for exporting antibiotic arbekacin sulfate to India
20102001
2010
06
Listed on Korea Stock Exchange
02
Central Research Center relocated (Dongbinggo-dong, Yongsan-gu, Seoul → Pyeongchon-dong, Dongan-gu, Anyang-si)
2009
03
Awarded model taxpayer citation (Minister of Strategy and Finance)
2008
01
Signed anticancer gene therapy joint development contract with ViroMed Co., Ltd.
2004
01
Signed joint development contract with ViroMed Co., Ltd. for vascular and neurological disease gene therapy drug
2003
12
Selected as an INNOBIZ company (Small and Medium Business Administration)
04
Selected as an excellent technology company (Korea Technology Finance Corporation)
20001950
2000
11
Developed Teicoplanin as a first generic API
03
Became the first company in Korea to release Arbekacin sulfate, which is specially effective against MRSA
01
Introduced original contrast agent (Optiray) product
1999
03
Synthesized antibiotic Arbekacin sulfate as a first generic manufacturer, and commenced export to Japan
1994
10
Completion of fermentation plant (located in Deoksan-eup, Jincheon-gun, Chungcheongbuk-do, Korea)
1991
03
Changed the company name from REYON Synthetics Co., Ltd. to REYON Pharmaceutical Co., Ltd.
1989
08
Completed construction of Jincheon Factory (located in Deoksan-eup, Jincheon-gun, Chungcheongbuk-do, Korea)
1988
01
Established affiliated REYON Central Research Center
1986
09
Joint development of Streptokinase,streptodornase (SKD) manufacturing technology (KIST)